Relay Therapeutics, Inc. (RLAY) announced encouraging interim data for their lead drug candidate, RLY-2608, in treating breast cancer.
The preliminary results indicate that, despite extensive prior treatments, patients with PI3Ka-mutated, HR+ (hormone receptor-positive), HER2- (human epidermal growth factor receptor 2-negative) breast cancer who received RLY-2608 combined with the FDA-approved drug fulvestrant experienced a clinically significant median progression-free survival (PFS) of 9.2 months. Almost 75% of patients showed tumor reduction.
Additionally, the combination of RLY-2608 and fulvestrant was generally well-tolerated across all dose levels as of the data cut-off date.
RLY-2608 is currently under investigation in ReDiscover, an ongoing first-in-human study designed to assess its safety, tolerability, pharmacokinetics, pharmacodynamics, and initial antitumor activity. The study includes RLY-2608 administered alone, in combination with fulvestrant, and in combination with fulvestrant and either ribociclib or atirmociclib.
